S00277-004-0850-2
Subgroup specific therapy effects in AML: AMLCG data.Transplantation strategies in AML: AMLCG data.Intensified induction therapy for children with AML.Modern diagnostics in chronic myeloproliferative diseases (CMPDs).Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells.Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).Role of MabCampath in allogeneic transplantation.Transplantation strategies in chronic lymphocytic leukemia: current concepts of the German CLL Study Group and the EBMT.New treatment strategies in lymphomas: aggressive lymphomas.Curative therapeutic approaches to APL.Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases.Genetic classification of acute myeloid leukemia (AML).Risk/MRD adapted GMALL trials in adult ALL.Maintenance therapy in childhood acute myeloid leukemia.Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.Novel treatment strategies in follicular lymphoma.Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461.Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults.Treatment of acute myeloid leukemia younger adults: the GOELAM experience.MRC trials in childhood acute myeloid leukaemia.Evolution of BFM trials for childhood ALL.PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.Epigenetic regulation of tumor suppressors in t(8:21)-containing AML.Targeted therapies in myeloid leukemiasThe recent JALSG study for newly diagnosed patients with acute promyelocytic leukemia (APL)Monitoring of minimal residual disease in acute promyelocytic leukemiaG3139, a BCL-2 antisense oligo-nucleotide, in AMLNew designs for phase II trials: application to a trial of targeted therapies vs. chemotherapy in patients age > 60 with AML/high-risk MDSAge and the nature of acute myeloid leukemiaPrognostic relevance of risk groups in the pediatric AML-BFM trials 93 and 98Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemiaThe U.S. trials in adult acute lymphoblastic leukemiaAutologous versus allogeneic stem cell transplantation in acute myeloid leukemia
P356
Q30928092-C4FB6810-A964-4FBB-96F8-A82BD25D1F65Q30928101-E7B47F65-AC46-4BF2-B234-252167B33ECCQ33202591-3651DFCE-0F4C-4D5D-8B4F-4C64278F194EQ35763592-630E5E42-CE22-4DB1-9526-502AABFEC38FQ35763596-5EC26232-FF9A-4AE8-BF16-6DDE662139C8Q35763600-F02ED39A-FDDF-4AD5-B6BC-99B4C4668E32Q35763603-2F5D37A9-DDC7-4B34-A98D-ADC2817C04F3Q35763607-39F42C45-5281-41E8-B3AE-48A9F8B840A6Q35763610-EF5028F7-4998-4A3F-8E19-97EE70C0C5F9Q35763615-A6299803-6F59-4E4C-8D38-685F145369ABQ35763618-F5239B5E-9897-4978-AED9-A11C4FCB8649Q35763622-804D1250-0CB4-40C7-9F54-B476A4E5082DQ40512939-AB8380DF-BCE6-4B3D-A712-0863EB3A5841Q44776469-C62AF02E-859A-4E3B-9B79-6F2331E1123AQ44881762-2248F4A8-ADC5-4DDD-A30D-B26067E795E3Q44881766-E1A2DD77-B606-4EF6-8652-279C7E144B92Q44881771-6DDA4B8C-52D3-46FD-982D-A7B110051B6CQ44881775-7A9B1D5B-8E36-4C85-BF37-383BC699C891Q44881780-76E25A67-937D-4C79-9B4F-9F2C891A2258Q44881782-31AD6ED6-7156-4A0F-B8F3-218A1DC8F383Q44881787-8EFF2892-2826-454A-A666-35E34B6890BFQ44881792-7BAF0C2C-8A60-4245-B48F-58DF562B6CA4Q47655625-BCDB655B-63ED-4C8B-BAD6-5CBFC17A9CDEQ47655663-82D3F984-B033-4ACE-B2D5-003CDC762C87Q95761695-CCABD8E2-94BA-49C4-91F9-42FA17C8FA96Q95761696-629E6D69-388B-40FD-9833-B6826F2F5F4FQ95761702-B82BD8E0-E4E1-4510-89DB-6BB1008FE1E0Q95761703-17BE84E9-5727-4DBE-A92D-3B8FC31E6BB8Q95761704-D43B0734-54A7-47DE-89B2-1CE1F9F74C67Q95761710-9048367E-2D4B-411E-AF1B-E87F0864A31BQ95761711-0D74F373-5A3F-4382-9A9D-90A0A571CCEFQ95761716-2D8A5DB0-3BDF-4E1A-85B0-9C6E0BD4C1B8Q95761718-69054860-2C08-41F0-9AA1-5EBE5796F69CQ95761719-107FA14A-5131-49E4-9763-CA001D28DF11